Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 16, 2026, 10:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 140 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Valsartan Clear all
Completed Phase 4 Interventional Results available

Aliskiren and Valsartan vs Valsartan Alone in Patients With Stage II Systolic Hypertension and Type II Diabetes Mellitus

NCT00927394
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Valsartan, Placebo for Aliskiren, Placebo for Valsartan
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
4
States / cities
Newark, Delaware • Kansas City, Missouri • Camden, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2012 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers

8-week Study to Evaluate Safety and Efficacy of Various Combinations of Valsartan, HCTZ, and Amlodipine in Patients With Moderate to Severe Hypertension

NCT00327587
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan + amlodipine, Valsartan + HCTZ, Amlodipine + HCTZ, Valsartan + amlodipine + HCTZ
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 85 Years
Enrollment
2,279 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 8, 2011 · Synced Oct 16, 2026, 10:49 PM EDT
Terminated Phase 2 Interventional Results available

Use of Entresto Sacubitril/Valsartan for the Treatment of Peripheral Arterial Disease

NCT02636283
View directory record Official record
Conditions
Peripheral Arterial Disease
Interventions
Entresto, Placebo group
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years to 80 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 17, 2019 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Protecting With ARNI Against Cardiac Consequences of Coronavirus Disease 2019

NCT04883528
View directory record Official record
Conditions
Covid19
Interventions
Sacubitril / Valsartan Oral Tablet [Entresto], Placebo
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 3 Interventional

A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Valsartan in Hypertensive Non Responders Patients

NCT00219193
View directory record Official record
Conditions
Hypertension
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
641 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 7, 2017 · Synced Oct 16, 2026, 10:49 PM EDT
No Longer Available No phase listed Expanded access

Multiple Patient Program to Ensure Access to LCZ696 Treatment to Patients Diagnosed With Heart Failure With Reduced Ejection Fraction (HF-rEF)

NCT02389933
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction (HF-rEF)
Interventions
LCZ696
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Vero Beach, Florida
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 16, 2026, 10:49 PM EDT
Completed No phase listed Observational

Sacubitril/Valsartan Treated Adult Patients With Chronic Heart Failure

NCT05613140
View directory record Official record
Conditions
Chronic Heart Failure
Interventions
sacubitril/valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
9,230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

Extension Study to Assess Long Term Safety, Tolerability, and Efficacy of Valsartan and Enalapril Combined and Alone in Children With Hypertension

NCT00446511
View directory record Official record
Conditions
Hypertension
Interventions
Valsartan, Enalapril, placebo matched to enalapril, placebo matched to valsartan
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
6 Years to 17 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 12, 2011 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 2 Interventional Results available

Effect of Valsartan on Carotid Artery Disease

NCT00208767
View directory record Official record
Conditions
Carotid Artery Diseases, Atherosclerosis
Interventions
Valsartan, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
21 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 8, 2015 · Synced Oct 16, 2026, 10:49 PM EDT
Recruiting Phase 1 Interventional

A Safety and Tolerability Study of HJB647 in Heart Failure Participants With Reduced Ejection Fraction

NCT07465653
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction
Interventions
HJB647 low dose, HJB647 high dose, Placebo
Drug · Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
5
States / cities
Bradenton, Florida • Inverness, Florida • Jacksonville, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 16, 2026, 10:49 PM EDT
Not listed Phase 4 Interventional

Effects of Valsartan and Aliskiren on Hemostatic Indices in Hypertensive Diabetics

NCT01095822
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Aliskiren + Valsartan
Drug
Lead sponsor
HeartDrug Research LLC
Other
Eligibility
21 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 30, 2010 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 4 Interventional Results available

Comparison of Sacubitril/Valsartan Versus Enalapril on Effect on NT-proBNP in Patients Stabilized From an Acute Heart Failure Episode.

NCT02554890
View directory record Official record
Conditions
Acute Heart Failure
Interventions
sacubitril/valsartan (LCZ696), Enalapril, sacubitril/valsartan (LCZ696) matching placebo, enalapril matching placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
887 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
123
States / cities
Birmingham, Alabama • Fort Smith, Arkansas • Little Rock, Arkansas + 105 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 2 Interventional Results available

The ENCHANTMENT HIV Study

NCT04153136
View directory record Official record
Conditions
HIV/AIDS, Heart Failure With Preserved Ejection Fraction
Interventions
Sacubitril-Valsartan 49-51Mg Oral Tablet, Placebo oral tablet
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
40 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 9, 2026 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 4 Interventional Results available

Mechanisms Underlying Hypotensive Response to ARB/NEP Inhibition - Aim 2

NCT04113109
View directory record Official record
Conditions
Heart Failure
Interventions
LCZ 696, Icatibant, placebo, Para-aminohippurate, Iohexol
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 4 Interventional Results available

Safety/Efficacy of Valsartan/Hydrochlorothiazide Combination Compared to Hydrochlorothiazide in Obese Hypertensive Adults

NCT00439738
View directory record Official record
Conditions
Hypertension
Interventions
HCTZ + Amlodipine, Valsartan/HCTZ
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
40 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
5
States / cities
Muscle Shoals, Alabama • Westlake Village, California • Oklahoma City, Oklahoma + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2017 · Synced Oct 16, 2026, 10:49 PM EDT
Completed No phase listed Observational

Effectiveness of Entresto (Sacubitril/Valsartan) in Japanese Patients With Hypertension

NCT06604897
View directory record Official record
Conditions
Essential Hypertension
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
20 Years to 99 Years
Enrollment
1,405 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 16, 2026, 10:49 PM EDT
Completed No phase listed Observational

Comparative Effectiveness of Entresto (Sacubitril/Valsartan) Versus ACEi/ARB in de Novo Heart Failure Patients

NCT05963282
View directory record Official record
Conditions
de Novo Heart Failure
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
9,870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 16, 2026, 10:49 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3

NCT00878969
View directory record Official record
Conditions
Oxidative Stress, Endothelial Dysfunction
Interventions
valsartan (ARB), ramipril (ACE inhibitor), Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 15, 2016 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

An Efficacy and Safety Study of Azilsartan Medoxomil Compared to Valsartan and Olmesartan in Participants With Essential Hypertension.

NCT00696436
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil, Valsartan, Olmesartan, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
86
States / cities
Alabaster, Alabama • Ozark, Alabama • Green Valley, Arizona + 83 more
Source: ClinicalTrials.gov public record
Updated Apr 19, 2011 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 2 Interventional Results available

Heart Failure Polypill at a Safety Net Hospital

NCT06029712
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction, HIV Infections
Interventions
Heart failure polypill, Control Rx
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 16, 2026, 10:49 PM EDT
Not yet recruiting Phase 1 Interventional

[11C]PS13 PET Imaging of Neuroinflammation in Heart Failure With Reduced Ejection Fraction

NCT07856043
View directory record Official record
Conditions
Heart Failure With Reduced Ejection Fraction, Cognitive Impairment, Mild, Neuroinflammation, Vascular Contributions to Cognitive Impairment and Dementia (VCID)
Interventions
[11C]PS13: [carbon-11]PS13; COX-1 PET radioligand, Sacubitril-Valsartan
Drug
Lead sponsor
Stony Brook University
Other
Eligibility
50 Years to 75 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Stony Brook, New York
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 16, 2026, 10:49 PM EDT
Not listed No phase listed Observational

Prospective Monitoring of Angiotensin Receptor Neprilysin Inhibitor in Older Adults With Heart Failure and Frailty

NCT04743063
View directory record Official record
Conditions
Heart Failure, Systolic, Frailty
Interventions
sacubitril/valsartan, Angiotensin II Receptor Blockers
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
65 Years and older
Enrollment
40,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 2 Interventional

Valsartan for Attenuating Disease Evolution In Early Sarcomeric HCM

NCT01912534
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Valsartan, Placebo
Drug
Lead sponsor
Carelon Research
Other
Eligibility
8 Years to 45 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
13
States / cities
Stanford, California • Aurora, Colorado • Chicago, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Oct 16, 2026, 10:49 PM EDT
Completed Phase 3 Interventional

A 10-12 Week Study to Evaluate the Safety and Efficacy of 320 mg Valsartan and 80 mg Simvastatin in Combination and as Monotherapies in Treating Hypertension and Hypercholesterolemia

NCT00171093
View directory record Official record
Conditions
HYPERTENSION, HYPERCHOLESTEROLEMIA
Interventions
valsartan + simvastatin
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 75 Years
Enrollment
369 participants
Timeline
Started 2004
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 23, 2017 · Synced Oct 16, 2026, 10:49 PM EDT